Connor, Clark & Lunn Investment Management (CC&L)’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-73,320
| Closed | -$20.2M | – | 1397 |
|
|
2024
Q3 | $20.2M | Buy |
73,320
+13,422
| +22% | +$3.69M | 0.1% | 169 |
|
|
2024
Q2 | $14.6M | Buy |
59,898
+44,455
| +288% | +$10.8M | 0.06% | 228 |
|
|
2024
Q1 | $2.31M | Buy |
+15,443
| New | +$2.31M | 0.01% | 631 |
|
|
2023
Q2 | – | Sell |
-12,901
| Closed | -$2.58M | – | 1298 |
|
|
2023
Q1 | $2.58M | Buy |
12,901
+11,661
| +940% | +$2.34M | 0.01% | 502 |
|
|
2022
Q4 | $295K | Buy |
+1,240
| New | +$295K | ﹤0.01% | 981 |
|
|
2021
Q3 | – | Sell |
-8,964
| Closed | -$1.52M | – | 1023 |
|
|
2021
Q2 | $1.52M | Sell |
8,964
-6,092
| -40% | -$1.03M | 0.01% | 600 |
|
|
2021
Q1 | $2.13M | Buy |
15,056
+4,683
| +45% | +$661K | 0.01% | 550 |
|
|
2020
Q4 | $1.35M | Buy |
+10,373
| New | +$1.35M | 0.01% | 584 |
|
|
2020
Q1 | – | Sell |
-1,850
| Closed | -$213K | – | 1003 |
|
|
2019
Q4 | $213K | Buy |
+1,850
| New | +$213K | ﹤0.01% | 827 |
|
|
2015
Q1 | – | Sell |
-5,100
| Closed | -$495K | – | 563 |
|
|
2014
Q4 | $495K | Buy |
+5,100
| New | +$495K | ﹤0.01% | 393 |
|
|
2014
Q1 | – | Sell |
-15,200
| Closed | -$1.04M | – | 673 |
|
|
2013
Q4 | $1.04M | Buy |
+15,200
| New | +$1.04M | 0.01% | 362 |
|